Multimodal Ayurveda therapeutic strategies and Yogic practices to impede the progression of nonalcoholic fatty liver disease to hepatocellular carcinoma: Opportunities and avenues - A narrative review
AYU (An International Quarterly Journal of Research in Ayurveda) · 2025-01 · 46 (1) · 4-13
DOI: 10.4103/ayu.ayu_261_24 ↗Kurz gefasst
Fachartikel in der Zeitschrift AYU (An International Quarterly Journal of Research in Ayurveda), online erschienen am 10.12.2025. Verfasst von E. Remya und 2 weiteren Autor:innen. Die Arbeit nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Background
Nonalcoholic fatty liver disease (NAFLD) is a growing global health concern, with a spectrum ranging from simple steatosis to hepatocellular carcinoma (HCC). Despite its increasing prevalence – particularly in Asia – there are currently no approved pharmacological treatments for NAFLD or nonalcoholic steatohepatitis. The disease’s progression is influenced by metabolic dysfunction, obesity, insulin resistance, and inflammatory processes. Existing therapeutic strategies focus on lifestyle modifications, but more personalized, integrative approaches are urgently needed.
Aims
To explore the Ayurvedic understanding of NAFLD and its progression to HCC and to propose a customized Ayurvedic and Yogic preventive-therapeutic protocol grounded in the individual-specific parameters of Agni (digestive/metabolic fire), (psycho-somatic constitution), Ama (metabolic toxins) etc. Materials and methods: A narrative review was conducted following SANRA guidelines. Literature was retrieved from PubMed, AYUSH Research Portal, and Google Scholar using the keywords such as NAFLD, HCC, Ayurveda, Agni, Prakriti , and Rasayana (rejuvenating therapy). Relevant literature and peer-reviewed articles obtained from these search engines and classical Ayurvedic compendia were reviewed, and data were analyzed thematically to identify the intersections between biomedical and Ayurvedic concepts.
Results
Ayurveda characterizes NAFLD as a Santarpanajanya Vyadhi (disease caused by excessive nourishment to the body) resulting from the impaired functions of Agni, Medodhatu (fat/adipose tissue), and Tridosha (bodily humors – Vata, Pitta , and Kapha ). A personalized protocol involving Agnideepana (stimulation of digestive fire), Shodhana (therapeutic purification therapy), hepatoprotective and rejuvenative formulations, and targeted Yogic practices was developed. This protocol is adaptable to phenotypic variations and disease stages.
Conclusion
Early implementation of a constitution-based Ayurvedic and Yogic regimen may prevent or decelerate NAFLD progression toward HCC. Integrating traditional knowledge systems with modern surveillance and stratification methods offers a promising, holistic approach to address the NAFLD–HCC continuum.
Zitieren
APA
Remya, E., Jameela, S., & Unnikrishnan, V. (2025). Multimodal Ayurveda therapeutic strategies and Yogic practices to impede the progression of nonalcoholic fatty liver disease to hepatocellular carcinoma: Opportunities and avenues - A narrative review. AYU (An International Quarterly Journal of Research in Ayurveda), 46(1), 4-13. https://doi.org/10.4103/ayu.ayu_261_24
Vancouver
Remya E, Jameela S, Unnikrishnan V. Multimodal Ayurveda therapeutic strategies and Yogic practices to impede the progression of nonalcoholic fatty liver disease to hepatocellular carcinoma: Opportunities and avenues - A narrative review. AYU (An International Quarterly Journal of Research in Ayurveda). 2025;46(1):4-13. doi:10.4103/ayu.ayu_261_24
BibTeX
@article{Remya2025,
author = {Remya, E. and Jameela, Sophia and Unnikrishnan, Vidhya},
title = {Multimodal Ayurveda therapeutic strategies and Yogic practices to impede the progression of nonalcoholic fatty liver disease to hepatocellular carcinoma: Opportunities and avenues - A narrative review},
journal = {AYU (An International Quarterly Journal of Research in Ayurveda)},
year = {2025},
volume = {46},
number = {1},
pages = {4--13},
doi = {10.4103/ayu.ayu_261_24}
}
EUVIMED